Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Traumatic life events and development of post-traumatic stress disorder among female factory workers in a developing country.

Fitch TJ, Yu X, Chien LC, Karim MM, Alamgir H.

Int J Soc Psychiatry. 2018 Jun;64(4):351-358. doi: 10.1177/0020764018761502. Epub 2018 Mar 8.

PMID:
29517393
2.

NCCN Guidelines Insights: Palliative Care, Version 2.2017.

Dans M, Smith T, Back A, Baker JN, Bauman JR, Beck AC, Block S, Campbell T, Case AA, Dalal S, Edwards H, Fitch TR, Kapo J, Kutner JS, Kvale E, Miller C, Misra S, Mitchell W, Portman DG, Spiegel D, Sutton L, Szmuilowicz E, Temel J, Tickoo R, Urba SG, Weinstein E, Zachariah F, Bergman MA, Scavone JL.

J Natl Compr Canc Netw. 2017 Aug;15(8):989-997. doi: 10.6004/jnccn.2017.0132.

PMID:
28784860
3.

Prevalence and risk factors of depression among garment workers in Bangladesh.

Fitch TJ, Moran J, Villanueva G, Sagiraju HKR, Quadir MM, Alamgir H.

Int J Soc Psychiatry. 2017 May;63(3):244-254. doi: 10.1177/0020764017695576. Epub 2017 Mar 1.

PMID:
28466750
4.

Forebrain-selective AMPA-receptor antagonism guided by TARP γ-8 as an antiepileptic mechanism.

Kato AS, Burris KD, Gardinier KM, Gernert DL, Porter WJ, Reel J, Ding C, Tu Y, Schober DA, Lee MR, Heinz BA, Fitch TE, Gleason SD, Catlow JT, Yu H, Fitzjohn SM, Pasqui F, Wang H, Qian Y, Sher E, Zwart R, Wafford KA, Rasmussen K, Ornstein PL, Isaac JT, Nisenbaum ES, Bredt DS, Witkin JM.

Nat Med. 2016 Dec;22(12):1496-1501. doi: 10.1038/nm.4221. Epub 2016 Nov 7.

PMID:
27820603
5.

Self-efficacy, disability level and physical strength in the injured workers: findings from a major factory disaster in Bangladesh.

Villanueva G, Fitch T, Quadir MM, Raju Sagiraju HK, Alamgir H.

Disabil Rehabil. 2017 Apr;39(7):677-683. doi: 10.3109/09638288.2016.1161085. Epub 2016 Apr 4.

PMID:
27043048
6.

Palliative Care Version 1.2016.

Levy M, Smith T, Alvarez-Perez A, Back A, Baker JN, Beck AC, Block S, Dalal S, Dans M, Fitch TR, Kapo J, Kutner JS, Kvale E, Misra S, Mitchell W, Portman DG, Sauer TM, Spiegel D, Sutton L, Szmuilowicz E, Taylor RM, Temel J, Tickoo R, Urba SG, Weinstein E, Zachariah F, Bergman MA, Scavone JL.

J Natl Compr Canc Netw. 2016 Jan;14(1):82-113.

PMID:
26733557
7.

Novel Small Molecule Agonist of TGR5 Possesses Anti-Diabetic Effects but Causes Gallbladder Filling in Mice.

Briere DA, Ruan X, Cheng CC, Siesky AM, Fitch TE, Dominguez C, Sanfeliciano SG, Montero C, Suen CS, Xu Y, Coskun T, Michael MD.

PLoS One. 2015 Aug 27;10(8):e0136873. doi: 10.1371/journal.pone.0136873. eCollection 2015.

8.

The prevalence and risk factors of Post-Traumatic Stress Disorder among workers injured in Rana Plaza building collapse in Bangladesh.

Fitch T, Villanueva G, Quadir MM, Sagiraju HK, Alamgir H.

Am J Ind Med. 2015 Jul;58(7):756-63. doi: 10.1002/ajim.22471. Epub 2015 May 12.

PMID:
25964138
9.

Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study.

Merchan JR, Qin R, Pitot H, Picus J, Liu G, Fitch T, Maples WJ, Flynn PJ, Fruth BF, Erlichman C.

Cancer Chemother Pharmacol. 2015 Mar;75(3):485-93. doi: 10.1007/s00280-014-2668-5. Epub 2015 Jan 3.

10.

Impact of race and ethnicity on outcomes and health care utilization after allogeneic hematopoietic cell transplantation.

Khera N, Chang YH, Slack J, Fauble V, Leis JF, Noel P, Sproat L, Palmer J, Adams R, Fitch T, Northfelt D, Guy M, Tilburt J, Mikhael J.

Leuk Lymphoma. 2015 Apr;56(4):987-92. doi: 10.3109/10428194.2014.941834. Epub 2014 Aug 20.

PMID:
25012944
11.

LSN2424100: a novel, potent orexin-2 receptor antagonist with selectivity over orexin-1 receptors and activity in an animal model predictive of antidepressant-like efficacy.

Fitch TE, Benvenga MJ, Jesudason CD, Zink C, Vandergriff AB, Menezes MM, Schober DA, Rorick-Kehn LM.

Front Neurosci. 2014 Jan 28;8:5. doi: 10.3389/fnins.2014.00005. eCollection 2014.

12.

Incidence and cost of nurse workplace violence perpetrated by hospital patients or patient visitors.

Speroni KG, Fitch T, Dawson E, Dugan L, Atherton M.

J Emerg Nurs. 2014 May;40(3):218-28; quiz 295. doi: 10.1016/j.jen.2013.05.014. Epub 2013 Sep 17.

PMID:
24054728
13.

Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer.

Northfelt DW, Allred JB, Liu H, Hobday TJ, Rodacker MW, Lyss AP, Fitch TR, Perez EA; North Central Cancer Treatment Group.

Am J Clin Oncol. 2014 Apr;37(2):167-71. doi: 10.1097/COC.0b013e31826e0550.

14.

The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9.

Barton DL, Burger K, Novotny PJ, Fitch TR, Kohli S, Soori G, Wilwerding MB, Sloan JA, Kottschade LA, Rowland KM Jr, Dakhil SR, Nikcevich DA, Loprinzi CL.

Support Care Cancer. 2013 Apr;21(4):1185-92. doi: 10.1007/s00520-012-1647-9. Epub 2012 Nov 13.

15.

North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane.

Sideras K, Dueck AC, Hobday TJ, Rowland KM Jr, Allred JB, Northfelt DW, Lingle WL, Behrens RJ, Fitch TR, Nikcevich DA, Perez EA.

Clin Breast Cancer. 2012 Dec;12(6):387-91. doi: 10.1016/j.clbc.2012.09.007. Epub 2012 Oct 17.

16.

Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial.

Tan WW, Allred JB, Salim M, Flynn P, Fishkin PA, Stella PJ, Wiesenfeld M, Bernath AM, Fitch TR, Perez EA.

Clin Breast Cancer. 2012 Apr;12(2):81-6. doi: 10.1016/j.clbc.2012.01.001.

17.

Analysis of chemical and physical effects of ultraviolet bulbs on cooking emissions.

Farrell FM, Fitch TM, Bicking MK.

J Air Waste Manag Assoc. 2011 Oct;61(10):1005-14.

PMID:
22070033
18.

Neoadjuvant chemoradiation compared to neoadjuvant radiation alone and surgery alone for Stage II and III soft tissue sarcoma of the extremities.

Curtis KK, Ashman JB, Beauchamp CP, Schwartz AJ, Callister MD, Dueck AC, Gunderson LL, Fitch TR.

Radiat Oncol. 2011 Aug 9;6:91. doi: 10.1186/1748-717X-6-91.

19.

Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52.

Bolton JS, O'Connell MJ, Mahoney MR, Farr GH Jr, Fitch TR, Maples WJ, Nagorney DM, Rubin J, Fuloria J, Steen PD, Alberts SR.

Clin Colorectal Cancer. 2012 Mar;11(1):31-7. doi: 10.1016/j.clcc.2011.03.029. Epub 2011 May 13.

20.

A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1).

Kottschade LA, Suman VJ, Amatruda T 3rd, McWilliams RR, Mattar BI, Nikcevich DA, Behrens R, Fitch TR, Jaslowski AJ, Markovic SN.

Cancer. 2011 Apr 15;117(8):1704-10. doi: 10.1002/cncr.25659. Epub 2010 Nov 8.

21.

Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial.

Alberts SR, Fitch TR, Kim GP, Morlan BW, Dakhil SR, Gross HM, Nair S.

Am J Clin Oncol. 2012 Aug;35(4):329-33. doi: 10.1097/COC.0b013e3182118cdf.

22.

A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C).

Okuno S, Bailey H, Mahoney MR, Adkins D, Maples W, Fitch T, Ettinger D, Erlichman C, Sarkaria JN.

Cancer. 2011 Aug 1;117(15):3468-75. doi: 10.1002/cncr.25928. Epub 2011 Feb 1.

23.

Phase II study of preoperative pemetrexed, carboplatin, and radiation followed by surgery for locally advanced esophageal cancer and gastroesophageal junction tumors.

Jatoi A, Soori G, Foster NR, Hiatt BK, Knost JA, Fitch TR, Callister MD, Nichols FC 3rd, Husted TM, Alberts SR.

J Thorac Oncol. 2010 Dec;5(12):1994-8. doi: 10.1097/JTO.0b013e3181fb5c3e.

24.

Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.

Von Hoff DD, Stephenson JJ Jr, Rosen P, Loesch DM, Borad MJ, Anthony S, Jameson G, Brown S, Cantafio N, Richards DA, Fitch TR, Wasserman E, Fernandez C, Green S, Sutherland W, Bittner M, Alarcon A, Mallery D, Penny R.

J Clin Oncol. 2010 Nov 20;28(33):4877-83. doi: 10.1200/JCO.2009.26.5983. Epub 2010 Oct 4.

PMID:
20921468
25.

CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma.

Laack NN, O'Neill BP, Ballman KV, O'Fallon JR, Carrero XW, Kurtin PJ, Scheithauer BW, Brown PD, Habermann TM, Colgan JP, Gilbert MR, Hawkins RB, Morton RF, Windschitl HE, Fitch TR, Pajon ER Jr; North Central Cancer Treatment Group and Mayo Clinic.

Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):476-82. doi: 10.1016/j.ijrobp.2010.06.002. Epub 2010 Aug 26.

26.

Journal club. A cognitive biologist foresees breakthroughs in understanding vocal learning.

Fitch T.

Nature. 2010 Jul 8;466(7303):163. doi: 10.1038/466163e. No abstract available.

PMID:
20613803
27.

A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422).

Jatoi A, Schild SE, Foster N, Henning GT, Dornfeld KJ, Flynn PJ, Fitch TR, Dakhil SR, Rowland KM, Stella PJ, Soori GS, Adjei AA.

Ann Oncol. 2010 Oct;21(10):2040-4. doi: 10.1093/annonc/mdq075. Epub 2010 Jun 21.

28.

North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer.

Perez EA, Hillman DW, Dentchev T, Le-Lindqwister NA, Geeraerts LH, Fitch TR, Liu H, Graham DL, Kahanic SP, Gross HM, Patel TA, Palmieri FM, Dueck AC.

Ann Oncol. 2010 Feb;21(2):269-74. doi: 10.1093/annonc/mdp512. Epub 2009 Nov 9.

29.

A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer.

Curtis KK, Hartney JT, Jewell RC, Park JW, Lebowitz PF, Griffin PP, Borad MJ, Fitch TR, Northfelt DW.

J Clin Pharmacol. 2010 Mar;50(3):268-75. doi: 10.1177/0091270009343699. Epub 2009 Oct 6.

PMID:
19808951
30.

Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.

Kim GP, Sargent DJ, Mahoney MR, Rowland KM Jr, Philip PA, Mitchell E, Mathews AP, Fitch TR, Goldberg RM, Alberts SR, Pitot HC.

J Clin Oncol. 2009 Jun 10;27(17):2848-54. doi: 10.1200/JCO.2008.20.4552. Epub 2009 Apr 20.

31.

A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB).

Loprinzi CL, Dueck AC, Khoyratty BS, Barton DL, Jafar S, Rowland KM Jr, Atherton PJ, Marsa GW, Knutson WH, Bearden JD 3rd, Kottschade L, Fitch TR.

Ann Oncol. 2009 Mar;20(3):542-9. doi: 10.1093/annonc/mdn644. Epub 2009 Jan 6.

32.

Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.

Perez DG, Suman VJ, Fitch TR, Amatruda T 3rd, Morton RF, Jilani SZ, Constantinou CL, Egner JR, Kottschade LA, Markovic SN.

Cancer. 2009 Jan 1;115(1):119-27. doi: 10.1002/cncr.23987.

33.

Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.

Moreno-Aspitia A, Morton RF, Hillman DW, Lingle WL, Rowland KM Jr, Wiesenfeld M, Flynn PJ, Fitch TR, Perez EA.

J Clin Oncol. 2009 Jan 1;27(1):11-5. doi: 10.1200/JCO.2007.15.5242. Epub 2008 Dec 1.

34.

Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943.

Alberts SR, Sande JR, Foster NR, Quevedo FJ, McWilliams RR, Kugler JW, Fitch TR, Jaslowski AJ.

J Gastrointest Cancer. 2007;38(2-4):87-94. doi: 10.1007/s12029-008-9037-8. Epub 2008 Nov 21.

PMID:
19023677
35.

Decision-making role preferences of patients receiving adjuvant cancer treatment: a university of Rochester cancer center community clinical oncology program.

Shields CG, Morrow GR, Griggs J, Mallinger J, Roscoe J, Wade JL, Dakhil SR, Fitch TR.

Support Cancer Ther. 2004 Jan 1;1(2):119-26. doi: 10.3816/SCT.2004.n.005.

PMID:
18628188
36.
37.

Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51).

Johnson EA, Marks RS, Mandrekar SJ, Hillman SL, Hauge MD, Bauman MD, Wos EJ, Moore DF, Kugler JW, Windschitl HE, Graham DL, Bernath AM Jr, Fitch TR, Soori GS, Jett JR, Adjei AA, Perez EA.

Lung Cancer. 2008 May;60(2):200-7. Epub 2007 Nov 28.

PMID:
18045731
38.

Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044).

Jatoi A, Martenson JA, Foster NR, McLeod HL, Lair BS, Nichols F, Tschetter LK, Moore DF Jr, Fitch TR, Alberts SR; North Central Cancer Treatment Group (N0044).

Am J Clin Oncol. 2007 Oct;30(5):507-13.

PMID:
17921712
39.

A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group.

Jatoi A, Dakhil SR, Nguyen PL, Sloan JA, Kugler JW, Rowland KM Jr, Soori GS, Wender DB, Fitch TR, Novotny PJ, Loprinzi CL.

Cancer. 2007 Sep 15;110(6):1396-403.

40.

Flutamide in men with prostatic intraepithelial neoplasia: a randomized, placebo-controlled chemoprevention trial.

Alberts SR, Novotny PJ, Sloan JA, Danella J, Bostwick DG, Sebo TJ, Blute ML, Fitch TR, Levitt R, Lieberman R, Loprinzi CL.

Am J Ther. 2006 Jul-Aug;13(4):291-7.

PMID:
16858161
41.

Phase II study of erlotinib in patients with advanced biliary cancer.

Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C.

J Clin Oncol. 2006 Jul 1;24(19):3069-74.

PMID:
16809731
42.

Locus of control and academic achievement in high school students.

Shepherd S, Owen D, Fitch TJ, Marshall JL.

Psychol Rep. 2006 Apr;98(2):318-22.

PMID:
16796083
43.

Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1.

Pockaj BA, Gallagher JG, Loprinzi CL, Stella PJ, Barton DL, Sloan JA, Lavasseur BI, Rao RM, Fitch TR, Rowland KM, Novotny PJ, Flynn PJ, Richelson E, Fauq AH.

J Clin Oncol. 2006 Jun 20;24(18):2836-41.

PMID:
16782922
44.

A Phase II NCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer.

Molina JR, Nikcevich D, Hillman S, Geyer S, Drevyanko T, Jett J, Verdirame J, Tazelaar H, Rowland K, Wos E, Kutteh L, Nair S, Fitch T, Flynn P, Stella P, Adjei AA.

Cancer Invest. 2006 Jun-Jul;24(4):382-9.

PMID:
16777690
45.

Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial.

Sideras K, Schaefer PL, Okuno SH, Sloan JA, Kutteh L, Fitch TR, Dakhil SR, Levitt R, Alberts SR, Morton RF, Rowland KM, Novotny PJ, Loprinzi CL.

Mayo Clin Proc. 2006 Jun;81(6):758-67.

PMID:
16770976
46.

Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer.

Schild SE, McGinnis WL, Graham D, Hillman S, Fitch TR, Northfelt D, Garces YI, Shahidi H, Tschetter LK, Schaefer PL, Adjei A, Jett J.

Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1106-11. Epub 2006 May 26.

PMID:
16730134
47.

Metastatic prostate carcinoma mimicking meningioma: case report and review of the literature.

Lyons MK, Drazkowski JF, Wong WW, Fitch TR, Nelson KD.

Neurologist. 2006 Jan;12(1):48-52. Review.

PMID:
16547447
48.

Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients > or = 65 years of age: an NCCTG study.

Baweja M, Suman VJ, Fitch TR, Mailliard JA, Bernath A, Rowland KM, Alberts SR, Kaur JS, Perez EA; NCCTG.

Ann Oncol. 2006 Apr;17(4):623-9. Epub 2006 Mar 6.

PMID:
16520332
49.

Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7.

Loprinzi CL, Levitt R, Barton D, Sloan JA, Dakhil SR, Nikcevich DA, Bearden JD 3rd, Mailliard JA, Tschetter LK, Fitch TR, Kugler JW.

J Clin Oncol. 2006 Mar 20;24(9):1409-14. Epub 2006 Feb 27.

PMID:
16505409
50.

Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points.

Dispenzieri A, Gertz MA, Lacy MQ, Geyer SM, Fitch TR, Fenton RG, Fonseca R, Isham CR, Ziesmer SC, Erlichman C, Bible KC.

Haematologica. 2006 Mar;91(3):390-3. Epub 2006 Feb 17.

Supplemental Content

Support Center